{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Non-small cell lung cancer (NSCLC)"},{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"11.0","upperLimit":"NA","value":"17.5"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"18.2","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Melanoma"},{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"7.6","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Renal cell cancer (RCC)"},{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"5.8","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Mesothelioma"},{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"7.6","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Triple negative breast cancer (TNBC)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"DOR only applies to subjects for whom best overall response is immune related complete response (irCR) or immune related partial response (irPR). DOR is defined as the time from the date of first documented response (irCR or irPR) to the date of first documented progression or death due to study indication. If a patient not had an event, duration was censored at the date of last adequate tumor assessment.\n\nTumor response was based on local investigator assessment and the assessment criteria was irRC.\n\nDOR is reported by tumor type.","dispersionType":"90% Confidence Interval","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"MEDIAN","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 or PDR001 and had a documented response (irCR or irPR).","reportingStatus":"POSTED","timeFrame":"From first documented response (irCR or irPR) to first documented progression or death due to study indication, assessed up to 2.6 years","title":"Phase 2: Duration of Response (DOR) Per irRC","type":"SECONDARY","unitOfMeasure":"months"}